Efficacy and Safety of a Biosimilar Liraglutide (Melitide ®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial

ConclusionThe biosimilar liraglutide (Melitide®) was noninferior in efficacy and comparable in safety when compared with the reference liraglutide.Trial RegistrationNCT03421119.

Source: Diabetes Therapy - October 12, 2023 Category: Endocrinology Source Type: research